DaVita Clinical Research Presents Research Results at the 33rd Annual Dialysis Conference

DaVita Clinical Research^® (DCR^®), a specialty contract research organization with services spanning the full spectrum of drug and device development, presented research results at the 33rd Annual Dialysis Conference (ADC) in Seattle, March 9-12, 2013.

This international conference has become an influential annual meeting in the dialysis and nephrology communities. The 2012 meeting attracted over 1,800 participants from more than 40 countries.

Researchers from DaVita^®, the dialysis division of DaVita Healthcare Partners Inc., and DCR presented results from a number of innovative clinical improvement programs originating from DaVita and its research partners. DCR provides a collaborative bridge between DaVita’s health care community and the academic, pharmaceutical and biotech research community. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

“Our goal at DaVita is to try to improve our patients’ quality of life. Research is a critical vehicle to achieve that end,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical research. “The work presented at ADC is intended to lead to better clinical outcomes and better quality of life for chronic kidney disease and end-stage renal disease patients around the world.”

ADC featured the following oral presentations by John Moran, M.D., F.A.C.P., vice president of medical affairs at DaVita:

• Urgent-Start Peritoneal Dialysis: A Clinical Process Improvement Report – Monday, March 11. Slide Forum IV, Clinical Studies & Experiences Part B.
• Implementation of Alcayis Protocol Markedly Improves Peritonitis Rates – Monday, March 11. Slide Forum IV, Clinical Studies & Experiences Part B.
• Decreasing Peritonitis Rate in PD Resulting in Lower Mortality and Technique Failure – Monday, March 11. Slide Forum I, Quality Improvement.

ADC also featured the following poster presentation:

• Association of Pruritis and Quality of Life (QOL) Among Patients at a Large Dialysis Provider (Bond TC, Mutell R, Wilfehrt HM, and Krishnan M.) – Sunday, March 10. Poster Forum I, Quality Improvement.

DaVita, DaVita Clinical Research, DCR and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita Healthcare Partners Inc. All other trademarks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Dec. 31, 2012, DaVita operated or provided administrative services at 1,954 outpatient dialysis centers located in the United States serving approximately 153,000 patients. The company also operated 36 outpatient dialysis centers located in eight countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners, Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of clinical trials including retrospective and prospective pragmatic trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR’s Biorepository, Early Clinical Research unit (Phase I-IIa) and Clinical Development (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes Research, Central Laboratory, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.